Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta, Prometheus Close Deal for miRNA Dx Market Rights


Rosetta Genomics this week announced that its previously announced license and collaboration deal with Prometheus Laboratories has closed.

The deal, unveiled earlier this month, gives Prometheus the US market rights to Rosetta's three microRNA-based diagnostics, including miRview Meso, which differentiates lung cancer from mesothelioma; miRview Mets, which is designed to determine the source of cancers of unknown primary origin; and miRview Squamous, which is designed to differentiate squamous from non-squamous non-small cell lung cancer (see RNAi News, 4/16/2009).

As part of the deal, Rosetta and Prometheus will also jointly develop two additional miRNA-based gastroenterology diagnostics.

The companies also said that Prometheus' planned purchase of 2 million shares of Rosetta at $4 per share has been completed.

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.